Related Experiment Video
Updated: Aug 7, 2026
A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
Published on: March 29, 2024
Diabetes mellitus and heart failure
Gary E Sander1, Thomas D Giles
1Section of Cardiology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Insights
Diabetes mellitus causes heart failure through various mechanisms. Early detection and aggressive management of cardiac abnormalities in diabetic patients are crucial for reducing cardiovascular disease and mortality.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Diseases
Background:
- Diabetes mellitus is linked to significant cardiovascular morbidity and mortality.
- Heart failure is a major complication, stemming from coronary atherosclerosis, hypertension, and diabetic cardiomyopathy.
- Metabolic abnormalities like hyperglycemia and insulin resistance contribute to cardiac structural changes and autonomic neuropathy.
Purpose of the Study:
- To emphasize the importance of early cardiac abnormality detection in diabetes.
- To advocate for aggressive management of cardiovascular risk factors in diabetic patients.
- To highlight the role of specific medications in reducing cardiovascular events.
Main Methods:
- Review of existing literature on diabetes and cardiovascular complications.
- Analysis of the impact of hyperglycemia, insulin resistance, and hypertension on cardiac structure and function.
- Evaluation of secondary prevention targets and pharmacological interventions.
Main Results:
- Diabetes significantly increases the risk of heart failure, independent of coronary artery disease.
- Activation of the renin-angiotensin-aldosterone system contributes to cardiac fibrosis.
- Aggressive control of blood pressure and lipids is essential.
Conclusions:
- Early identification of cardiac issues in diabetic patients is imperative.
- Treatment should aim for secondary prevention targets (BP < 130/80 mmHg, LDL-C < 100 mg/dL).
- Pharmacological agents like ACE inhibitors, ARBs, beta-blockers, statins, and aspirin reduce cardiovascular risk.
Abstract:
The metabolic abnormalities associated with diabetes mellitus result in macrovascular and microvascular complications in multiple organ systems; it is the cardiovascular impact that accounts for the greatest morbidity and mortality associated with this disease. Heart failure, both with reduced and preserved systolic function, is a major complication, arising from the frequent associations with coronary atherosclerosis, hypertension, and a specific heart muscle dysfunction (cardiomyopathy) that occurs independently of coronary artery disease. Hyperglycemia, insulin resistance, and hypertension, together with activation of both the circulating and the tissue renin-angiotensin-aldosterone systems, contribute to structural fibrosis and autonomic neuropathy. Thus, it becomes imperative to identify cardiac abnormalities early in the course of both type 1 and type 2 diabetes to allow early and aggressive intervention to control glucose and blood pressure and to normalize blood lipid profiles. Patients with diabetes should be treated to secondary prevention targets, including blood pressure less than 130/80 mm Hg and low-density lipoprotein cholesterol level less than 100 mg/dL. Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers,beta blockers, calcium channel-blockers, statins, and aspirin have all been demonstrated to significantly reduce cardiovascular morbidity and mortality in patients with diabetes.
Related Concept Videos
01:17Pathophysiology of Heart Failure
01:22Heart Failure Drugs: Diuretics
01:27Heart Failure I: Introduction
01:29Heart Failure II: Pathophysiology
01:30Heart Failure IV: Classification and Diagnostic Evaluation
01:22Complications of Diabetes Mellitus